Posted: 3 November 2023
Optiscan Imaging Limited (ASX: OIL) is pleased to announce a key leadership appointment reflecting the continued commercial expansion of the Company.
The Company is delighted to announce the appointment of Brendan Fafiani to the role of Chief Operating Officer. Effective 6 November 2023, Brendan will assume responsibility for Optiscan’s operations at its Melbourne headquarters, leading the development of the Company’s operational planning and overseeing its commercialisation strategy encompassing sales and marketing, as well as managing personnel, and customer and development efforts. Optiscan CEO, Dr Camile Farah, will continue to focus on key investor relations, stakeholder engagement initiatives, and the US expansion plan.
Brendan joins Optiscan from Cyban Pty Ltd, where, as the Chief Executive Officer he led the initial commercialisation of a pioneering non-invasive Brain Oxygen and Intracranial Pressure monitor. Prior to this, as Vice President of Product and General Manager at Global Kinetics, Brendan led the product development of a novel Parkinson’s disease monitor through regulatory clearance and launch into the US, Europe, and APAC. Prior to relocating to Australia, as Associate Director Operations within Merck KGaA’s Medical Device Global Business Franchise, headquartered in Switzerland, he was responsible for the lifecycle management of a large portfolio of device and digital technologies.
Brendan brings a wealth of expertise in the introduction of new technologies into existing treatment pathways, both in start-ups undergoing rapid growth and large multinational corporations, across neurodegenerative and cardiometabolic diseases, endocrinology and acquired brain injury fields.
Optiscan CEO and Managing Director Dr Camile Farah, stated, “The appointment of Brendan follows a thorough and comprehensive executive search as we move beyond our inflection point in FY23, and pivot into accelerating revenue generation in FY24 and beyond. I am delighted to welcome Brendan into Optiscan to lead key elements of our business, shape and implement key commercial excellence processes and scale our operation.”
The decision to appoint a Chief Operating Officer is a key enablement strategy for Optiscan. It enhances the functionality of the Company’s global headquarters in Melbourne, facilitates integration with its US commercial hub, and advances pursuit of key strategic priorities that will benefit the Company and shareholder base greatly in the future.
Dr Camile Farah, continued, “Brendan brings the ideal blend of skills and expertise crucial for our current growth phase, aligning perfectly with planned product innovation, development of new clinical devices, and evolution into a digital solutions company offering revolutionary image guided surgical solutions coupled with proprietary world-class Artificial Intelligence (AI) and Telepathology diagnostic support functionality. I look forward to working closely with Brendan at our Melbourne headquarters, while continuing to focus on our US expansion plans. I will provide further updates on additional appointments and initiatives in due course.”
